Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Modified-Release Drug Delivery Systems: Bioavailability01:30

Modified-Release Drug Delivery Systems: Bioavailability

Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vutrisiran Health Care Resource Utilization, Costs, Discontinuation, and Mortality: A Real-World Claims Analysis.

Advances in therapy·2026
Same author

Dynamic Versus Static Cardiac Biomarker Assessment for Prognostic Stratification After Percutaneous Coronary Intervention: A Systematic Review.

Cureus·2026
Same author

Infection prevention and control practices in hospitals across Pakistan: a nationwide assessment using the WHO infection prevention and control assessment framework.

The Journal of hospital infection·2026
Same author

Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial.

Journal of cardiac failure·2026
Same author

A Systematic Review of Kernel-Level Security Mechanisms, Vulnerability Detection and Mitigation in Modern Operating Systems.

Sensors (Basel, Switzerland)·2026
Same author

Evolution of patient characteristics and outcomes in ATTR-CM clinical trials: A systematic review.

Progress in cardiovascular diseases·2026

Related Experiment Video

Updated: Jun 20, 2026

Application and Methodology of the Non-destructive 19F Time-domain NMR Technique to Measure the Content in Fluorine-containing Drug Products
09:24

Application and Methodology of the Non-destructive 19F Time-domain NMR Technique to Measure the Content in Fluorine-containing Drug Products

Published on: August 22, 2017

Dexlansoprazole MR.

Naeem Aslam1, Richard Wright

  • 1University of Louisville, Division of Gastroenterology/Hepatology, Department of Medicine, Kentucky 40292, USA.

Expert Opinion on Pharmacotherapy
|August 28, 2009
PubMed
Summary

Dexlansoprazole dual delayed release (DDR) offers improved acid control compared to traditional proton pump inhibitors (PPIs). Its unique dual release mechanism and R-enantiomer metabolism show potential for enhanced gastroesophageal symptom management.

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Drug Development

Background:

  • Proton pump inhibitors (PPIs) are widely used for gastroesophageal illnesses but often fail to provide 24-hour symptom control.
  • Dexlansoprazole dual delayed release (DDR) was developed to offer extended action and superior acid suppression.
  • The R-enantiomer's slower metabolism contributes to dexlansoprazole's prolonged efficacy.

Purpose of the Study:

  • To review the pharmacology of dexlansoprazole DDR.
  • To summarize available studies on dexlansoprazole DDR efficacy.
  • To highlight the unique pharmacokinetic profile of dexlansoprazole DDR.

Main Methods:

  • Literature review of all available medical studies on dexlansoprazole DDR.
  • Analysis of pharmacological data and clinical trial results.

Related Experiment Videos

Last Updated: Jun 20, 2026

Application and Methodology of the Non-destructive 19F Time-domain NMR Technique to Measure the Content in Fluorine-containing Drug Products
09:24

Application and Methodology of the Non-destructive 19F Time-domain NMR Technique to Measure the Content in Fluorine-containing Drug Products

Published on: August 22, 2017

  • Synthesis of evidence on efficacy and safety.

    • Main Results:

    • Dexlansoprazole DDR exhibits a novel dual delayed release formulation.
    • Pharmacokinetic studies indicate sustained drug levels and prolonged acid suppression.
    • Clinical data suggest improved symptom control in patients with gastroesophageal conditions.

    Conclusions:

    • Dexlansoprazole DDR demonstrates potential to surpass traditional PPIs in efficacy.
    • Its unique metabolism and dual release pharmacokinetics are key advantages.
    • Currently FDA-approved for treating erosive esophagitis and symptomatic gastroesophageal reflux disease.